Filing Flows › Xilio Therapeutics (XLO) › Q2 2026 › vs Q2 2025
Xilio Therapeutics (XLO) Q2 2026 vs Q2 2025 (year over year)
Xilio Therapeutics's revenue rose $10.6M (+131%) from $8.1M in Q2 2025 to $18.7M in Q2 2026.
Xilio Therapeutics, Q2 2026: revenue $18.7M (+131% year over year), operating margin -18.7%, net loss $6.4M, operating cash flow −$18.8M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $18.7M | $8.1M | $10.6M | +131% |
| Net loss | $6.4M | $15.8M | −$9.5M | -60% |
| Costs & expenses | $25.1M | $23.9M | $1.1M | +5% |
| Operating costs | $22.2M | $22.4M | −$267K | -1% |
| Interest & other, net | $2.9M | $1.5M | $1.4M | +95% |
| Research & development | $14.6M | $15.3M | −$771K | -5% |
| General & admin | $7.6M | $7.1M | $504K | +7% |
| Operating cash sources | $20.7M | $16.2M | $4.5M | +28% |
| Depreciation & amortization | $331K | $381K | −$50K | -13% |
| Share-based compensation | $1.6M | $1.4M | $247K | +18% |
| Cash used in operations | $18.8M | $14.5M | $4.3M | +30% |
| Net loss absorbed | $6.4M | $15.8M | −$9.5M | -60% |
| Working capital & other | $14.3M | $365K | $14.0M | 39× |
Questions
How much did Xilio Therapeutics's revenue grow year over year in Q2 2026?
Xilio Therapeutics's revenue rose $10.6M (+131%) from $8.1M in Q2 2025 to $18.7M in Q2 2026.